Skip to content

CONTRIBUTORS

Serena Perin Vinton, CFA

Portfolio Manager
United States

Joyce Lin, CFA

Portfolio Manager
Co-Director of Research
United States

Robert Rendler, CFA

Portfolio Manager
Research Analyst
United States

The latest industrial transformation appears to be here and is accelerating due to the pace of innovation and the need to build resiliency in the system. The COVID-19 pandemic, trade war and geopolitical instability each highlighted the dangers of overly concentrated supply chains and long lead times. Manufacturers experienced the pressures of supply-chain risk as unfilled orders, delayed shipments and surging prices wreaked short-term havoc on their business models. Companies are now accelerating the evaluation of reshoring or nearshoring manufacturing capabilities to build better flexibility into their operations. The factory of the future is going to go beyond simply adopting new technologies and digitalization: We believe concepts such as resiliency and sustainability will be a cornerstone of their design. From a technology perspective, this transformation will encompass automation, robotics, smart systems, virtualization, Internet of Things (IoT), big data analysis, machine learning and artificial intelligence (AI).

Topics covered in this publication include:

  • Industrial digitalization
  • Sustainability and resiliency
  • Massive capital investments

Read the full paper to learn more about the next industrial renaissance.

WHAT ARE THE RISKS?

All investments involve risks, including possible loss of principal.

Equity securities are subject to price fluctuation and possible loss of principal.

To the extent the portfolio invests in a concentration of certain securities, regions or industries, it is subject to increased volatility.

Investments in fast-growing industries like the technology and health care sectors (which have historically been volatile) could result in increased price fluctuation, especially over the short term, due to the rapid pace of product change and development and changes in government regulation of companies emphasizing scientific or technological advancement or regulatory approval for new drugs and medical instruments.

IMPORTANT LEGAL INFORMATION

This material is intended to be of general interest only and should not be construed as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice.

The views expressed are those of the investment manager and the comments, opinions and analyses are rendered as at publication date and may change without notice. The information provided in this material is not intended as a complete analysis of every material fact regarding any country, region or market.

Data from third party sources may have been used in the preparation of this material and Franklin Templeton Investments (“FTI”) has not independently verified, validated or audited such data. FTI accepts no liability whatsoever for any loss arising from use of this information and reliance upon the comments opinions and analyses in the material is at the sole discretion of the user.

Products, services and information may not be available in all jurisdictions and are offered outside the U.S. by other FTI affiliates and/or their distributors as local laws and regulation permits. Please consult your own professional adviser or Franklin Templeton institutional contact for further information on availability of products and services in your jurisdiction.

Issued by Franklin Templeton Investments Corp., 200 King Street West, Suite 1500 Toronto, ON, M5H3T4, Fax: (416) 364-1163, (800) 387-0830, www.franklintempleton.ca.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.